Hosted on MSN4d
AbbVie Falls 8% in 3 Months: Buy, Hold or Sell the Stock?
AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...
The Motley Fool27d
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
What I like about AbbVie is the strong growth from its Skyrizi and Rinvoq autoimmune drugs covering conditions like psoriatic arthritis, Crohn's disease, and rheumatoid arthritis through different ...
The Motley Fool26d
2 Excellent Dividend Stocks to Buy on the Dip
The most important therapies in its lineup that are helping smooth out Humira-related losses are the immunology superstars Skyrizi and Rinvoq. In the third quarter, AbbVie's top line increased by ...
Benzinga.com1mon
Kevin K Buckbee Executes Sell Order: Offloads $310K In AbbVie Stock
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.